# ATP-fueled STING activation of manganese coordinated nanoagonist to boost antitumor immunity

**Authors:** Si-Yao Han, Sui-Juan Zheng, Jia-Qi Luo, Hui-Han Yu, Xiao-Yue Liu, Jin-Zhi Du

PMC · DOI: 10.1016/j.bioactmat.2026.02.012 · Bioactive Materials · 2026-02-10

## TL;DR

Researchers developed an ATP-powered nanoparticle that boosts immune response against tumors by activating the STING pathway and reprogramming immune cells.

## Contribution

A novel ATP-Mn coordination nanoparticle is introduced to enhance STING activation and antitumor immunity.

## Key findings

- ATP-Mn CNP activates cGAS-STING signaling and shifts macrophages to an antitumor phenotype.
- ATP-Mn CNP combined with checkpoint inhibitors eradicated tumors in 37.5% of mice and prolonged survival.
- The nanoparticle effectively enhances cytotoxic lymphocyte infiltration into tumors.

## Abstract

The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway represents a central driver of innate immune activation, and manganese ion (Mn2+) has recently been identified as a potent modulator of this signaling axis. However, the application of Mn2+ is limited by its rapid clearance, nonspecific distribution and potential neurotoxicity. Inspired by the unique chemical structure and biological functions of adenosine triphosphate (ATP), we herein propose an ATP-Mn coordination nanoparticle (ATP-Mn CNP) to fuel cGAS-STING activation and antitumor immunity. We demonstrated that the phosphate groups of ATP could coordinate with Mn2+ and form stable, well-defined nanoparticles after lipid coating. ATP-Mn CNP significantly increased the expression of cGAS-STING-associated genes and activated the corresponding signaling cascades, and thus effectively polarized macrophages from tumor-supportive M2 to antitumor M1 phenotype. In vivo antitumor studies indicated that ATP-Mn CNP treatment significantly suppressed tumor growth, and reprogramed macrophages in tumors and draining lymph nodes, which thus facilitated the tumor infiltration of cytotoxic lymphocytes. Combination of ATP-Mn CNP with immune checkpoint inhibitors achieved 37.5% tumor eradication in MC38 murine models, and significantly prolonged mice survival. This study establishes an ATP-fueled coordination strategy that harnesses ATP as both an assembly ligand and an immune stimulator to enhance Mn-mediated STING activation.

Image 1

•ATP-Mn coordination nanoparticle (ATP-Mn CNP) synergistically potentiates cGAS-STING activation for cancer immunotherapy.•ATP not only drives the nanoparticle formation but synergizes with Mn2+ to amplify STING signaling.•ATP-Mn CNP reprograms macrophages and enhances cytotoxic lymphocyte infiltration in tumors.•Combining ATP-Mn CNP with checkpoint blockade achieves durable tumor suppression.

ATP-Mn coordination nanoparticle (ATP-Mn CNP) synergistically potentiates cGAS-STING activation for cancer immunotherapy.

ATP not only drives the nanoparticle formation but synergizes with Mn2+ to amplify STING signaling.

ATP-Mn CNP reprograms macrophages and enhances cytotoxic lymphocyte infiltration in tumors.

Combining ATP-Mn CNP with checkpoint blockade achieves durable tumor suppression.

## Linked entities

- **Genes:** CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004], STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061]
- **Chemicals:** ATP (PubChem CID 5957), Mn2+ (PubChem CID 27854)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Cd247 (CD247 antigen) [NCBI Gene 12503] {aka 4930549J05Rik, A430104F18Rik, Cd3, Cd3-eta, Cd3-zeta, Cd3h}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Cnp (2',3'-cyclic nucleotide 3' phosphodiesterase) [NCBI Gene 12799] {aka CNPase, Cnp-1, Cnp1}, Cgas (cyclic GMP-AMP synthase) [NCBI Gene 214763] {aka E330016A19Rik, Mb21d1}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}, Isg15 (ISG15 ubiquitin-like modifier) [NCBI Gene 100038882] {aka G1p2, IGI15, IP17, Irfp, UCRP}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, Itgax (integrin alpha X) [NCBI Gene 16411] {aka Cd11c, Cr4, N418}, Tbk1 (TANK-binding kinase 1) [NCBI Gene 56480] {aka 1200008B05Rik}, Isg20 (interferon-stimulated protein) [NCBI Gene 57444] {aka 1600023I01Rik, 2010107M23Rik, 20kDa, DnaQL, HEM45}, Cd69 (CD69 antigen) [NCBI Gene 12515] {aka 5830438K24Rik, AIM, VEA}, Ifnb1 (interferon beta 1, fibroblast) [NCBI Gene 15977] {aka IFN-beta, IFNB, If1da1, Ifb}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, alp (alopecia, recessive) [NCBI Gene 11691]
- **Diseases:** colorectal cancer (MESH:D015179), weight loss (MESH:D015431), Cytotoxicity (MESH:D064420), organ toxicity (MESH:D019965), B16 tumor (MESH:D008546), melanoma (MESH:D008545), inflammatory (MESH:D007249), Tumor (MESH:D009369), neurotoxicity (MESH:D020258), hemolysis (MESH:D006461), damage (MESH:D020263)
- **Chemicals:** TPP (MESH:C005692), H&amp;E (MESH:D006371), LysoTracker (MESH:C493330), H2O2 (MESH:D006861), ATP-Mn (-), cGAMP (MESH:C584311), lipid (MESH:D008055), 1,2-dioleoyl-sn-glycero-3-phosphocholine (MESH:C017251), ATP (MESH:D000255), DAPI (MESH:C007293), Manganese (MESH:D008345), CREA (MESH:D003404), glucose (MESH:D005947), PBS (MESH:D007854), DSPE-PEG2000 (MESH:C519184), hexanol (MESH:D000441), O (MESH:D010100), P (MESH:D010758), inorganic phosphate (MESH:D010710), GTP (MESH:D006160), metal (MESH:D008670), C (MESH:D002244), CDA (MESH:C528998), Triton X-100 (MESH:D017830), 1,2-dioleoyl-sn-glycero-3-phosphate (MESH:C037657), N (MESH:D009584), UA (MESH:D014527), DiD (MESH:D017878), water (MESH:D014867), cholesterol (MESH:D002784), CNP (MESH:C010422), cyclohexane (MESH:C506365), manganese oxide (MESH:C027424), MnCl2 (MESH:C025340), adenine (MESH:D000225)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), MC38 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_B288), B16-Luc — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_A4CK), MC38-Luc — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_0A67), B16 — Mus musculus (Mouse), Hybridoma (CVCL_U043), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914834/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914834/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914834/full.md

---
Source: https://tomesphere.com/paper/PMC12914834